155 related articles for article (PubMed ID: 16986263)
21. Model-based drug development: a rational approach to efficiently accelerate drug development.
Milligan PA; Brown MJ; Marchant B; Martin SW; van der Graaf PH; Benson N; Nucci G; Nichols DJ; Boyd RA; Mandema JW; Krishnaswami S; Zwillich S; Gruben D; Anziano RJ; Stock TC; Lalonde RL
Clin Pharmacol Ther; 2013 Jun; 93(6):502-14. PubMed ID: 23588322
[TBL] [Abstract][Full Text] [Related]
22. How clinical trials of myasthenia gravis can inform pre-clinical drug development.
Rostedt Punga A; Kaminski HJ; Richman DP; Benatar M
Exp Neurol; 2015 Aug; 270():78-81. PubMed ID: 25592627
[TBL] [Abstract][Full Text] [Related]
23. Animal intelligence.
Hoag H
Nature; 2006 May; 441(7092):544-5. PubMed ID: 16789060
[No Abstract] [Full Text] [Related]
24. [The discovery process in the pharmaceutical industry].
Scatton B
J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
[TBL] [Abstract][Full Text] [Related]
25. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
Sistare FD; DeGeorge JJ
Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
[TBL] [Abstract][Full Text] [Related]
26. Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.
Wong H; Bohnert T; Damian-Iordache V; Gibson C; Hsu CP; Krishnatry AS; Liederer BM; Lin J; Lu Q; Mettetal JT; Mudra DR; Nijsen MJMA; Schroeder P; Schuck E; Suryawanshi S; Trapa P; Tsai A; Wang H; Wu F
Drug Discov Today; 2017 Oct; 22(10):1447-1459. PubMed ID: 28476536
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers: a valuable tool in clinical research and medical practice.
Carini C
IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
[TBL] [Abstract][Full Text] [Related]
28. MRI in preclinical drug development.
Silva MD; Chandra S
Methods Mol Med; 2006; 124():299-322. PubMed ID: 16506427
[TBL] [Abstract][Full Text] [Related]
29. The Potential of Adaptive Design in Animal Studies.
Majid A; Bae ON; Redgrave J; Teare D; Ali A; Zemke D
Int J Mol Sci; 2015 Oct; 16(10):24048-58. PubMed ID: 26473839
[TBL] [Abstract][Full Text] [Related]
30. An integrative paradigm to impart quality to correlative science.
Kalos M
J Transl Med; 2010 Mar; 8():26. PubMed ID: 20233418
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial simulation in drug development.
Bonate PL
Pharm Res; 2000 Mar; 17(3):252-6. PubMed ID: 10801212
[TBL] [Abstract][Full Text] [Related]
32. Testing time for stem cells.
Baker M
Nature; 2010 Feb; 463(7282):719. PubMed ID: 20148005
[No Abstract] [Full Text] [Related]
33. Design and analysis of drug combination experiments.
Straetemans R; O'Brien T; Wouters L; Van Dun J; Janicot M; Bijnens L; Burzykowski T; Aerts M
Biom J; 2005 Jun; 47(3):299-308. PubMed ID: 16053254
[TBL] [Abstract][Full Text] [Related]
34. Effective integration of systems biology, biomarkers, biosimulation, and modeling in streamlining drug development.
Krishna R; Schaefer HG; Bjerrum OJ
J Clin Pharmacol; 2007 Jun; 47(6):738-43. PubMed ID: 17463216
[No Abstract] [Full Text] [Related]
35. An efficient method for the detection and elimination of systematic error in high-throughput screening.
Makarenkov V; Zentilli P; Kevorkov D; Gagarin A; Malo N; Nadon R
Bioinformatics; 2007 Jul; 23(13):1648-57. PubMed ID: 17463024
[TBL] [Abstract][Full Text] [Related]
36. [Should the pharmaceutical industry play an active part in pharmacosurveillance? (author's transl)].
d'Azemar P; Alexandre C; Thomas J
Anesth Analg (Paris); 1980; 37(9-10):537-42. PubMed ID: 7469070
[TBL] [Abstract][Full Text] [Related]
37. Predictive in vivo animal models and translation to clinical trials.
Cook N; Jodrell DI; Tuveson DA
Drug Discov Today; 2012 Mar; 17(5-6):253-60. PubMed ID: 22493784
[TBL] [Abstract][Full Text] [Related]
38. Consider drug efficacy before first-in-human trials.
Kimmelman J; Federico C
Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
[No Abstract] [Full Text] [Related]
39. The challenge of implementing high-throughput technologies in clinical trials.
Mocellin S; Marincola FM
Pharmacogenomics; 2005 Jun; 6(4):435-8. PubMed ID: 16004562
[No Abstract] [Full Text] [Related]
40. Anesthetic neuroprotection: antecedents and an appraisal of preclinical and clinical data quality.
Ishida K; Berger M; Nadler J; Warner DS
Curr Pharm Des; 2014; 20(36):5751-65. PubMed ID: 24502575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
